PRICELINE COLD & FLU tablets PE blister pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

priceline cold & flu tablets pe blister pack

soul pattinson manufacturing pty ltd - codeine phosphate hemihydrate,paracetamol,phenylephrine hydrochloride -

PHARMACY HEALTH COLD & FLU tablets PE blister pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacy health cold & flu tablets pe blister pack

soul pattinson manufacturing pty ltd - codeine phosphate hemihydrate,paracetamol,phenylephrine hydrochloride -

PHARMACIST COLD & FLU DAY PE tablet blister pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pharmacist cold & flu day pe tablet blister pack

pharmacare laboratories pty ltd - codeine phosphate hemihydrate,paracetamol,phenylephrine hydrochloride -

SOUL PATTINSON COLD & FLU TABLETS PE blister pack Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

soul pattinson cold & flu tablets pe blister pack

soul pattinson manufacturing pty ltd - codeine phosphate hemihydrate,paracetamol,phenylephrine hydrochloride -

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE solution Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

promethazine hydrochloride and codeine phosphate solution

akorn - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - codeine phosphate 10 mg in 5 ml - promethazine hcl and codeine phosphate oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. important limitations of use: promethazine hcl and codeine phosphate oral solution is contraindicated for: promethazine hcl and codeine phosphate oral solution is also contraindicated in patients with: risk summary promethazine hcl and codeine phosphate oral solution is not recommended for use in pregnant women, including during or immediately prior to labor. prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.19), clinical considerations ]. there are no available data with promethazine hcl and codeine phosphate oral solution use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. published studies with codeine have reported inconsistent findings and have important methodological limitations (see